- 中文名称
Anti-Human CCL-22
- 英文名字
- Anti-Human CCL-22
- 供应商
- ReliaTech
- 产品货号
- 101-M266
- 产品报价
- ￥询价/100ug
- 产品说明书
- 点击查看
- 购买方式
- 90%产品中国有现货库存。银行转账、电汇、支票、现金，在线支付宝及网银支付，或直接与我们电话联系400-6800-868
- 产品新闻
- 背景资料
- CCL22, also named stimulated T cell chemotactic protein (STCP1) and MDC, is a CC chemokine initially isolated from clones of monocytederived macrophages. Human CCL22 cDNA encodes a precursor protein of 93 amino acid residues with a 24 amino acid residue predicted signal peptide that is cleaved to yield a 69 amino acid residue mature 8 kDa protein. At the amino acid sequence level, CCL22 shows less than 35% identity to other CC chemokine family members. Human CCL22 is expressed in dendritic cells, macrophages and activated monocytes. In addition, CCL22 expression is also detected in the tissues of thymus, lymph node and appendix. The gene for human CCL22 has been mapped to chromosome 16 rather than chromosome 17 where the genes for many human CC chemokines are clustered. Recombinant or chemically synthesized mature CCL22 has been shown to induce chemotaxis or Ca2+ mobilization in dendritic cells, IL2 activated NK cells, and activated T lymphocytes. A CD8+ T lymphocytederived secreted soluble activity that suppresses infection by primary non-syncytium-inducing and syncytium-inducing HIV1 isolates and the T cell lineadapted isolate HIV1 IIIB, has been identified as CCL22. Based on aminoterminal sequence analysis, the major CD8 + T lymphocyte-derived CCL22 protein yielded an amino-terminal sequence of YGANM, which is two amino acid residues shorter than the predicted mature CCL22. The difference in potency between the two mature CCL22 isoforms has not been determined.
- 应用类型
- WB, N
- 免疫原
- 该Anti-Human CCL-22的详细信息查看ReliaTech提供的产品说明书。
- 来源宿主
- 该Anti-Human CCL-22的详细信息查看ReliaTech提供的产品说明书。
- 反应性
- 该Anti-Human CCL-22的详细信息查看ReliaTech提供的产品说明书。
- 保存建议
- 该Anti-Human CCL-22的详细信息查看ReliaTech提供的产品说明书。溶解建议：Centrifuge vial prior to opening. Reconstitute the antibody with 500 µl sterile PBS and the final concentration is 200 µg/ml.
- 其他
- ReliaTech全称为受体配体技术有限公司 (Receptor Ligand Technologies GmbH)，1999年成立，总部位于德国不伦瑞克，是一家后基因组生物技术公司。ReliaTech主要专注于受体和配体的发现与研究。此外，ReliaTech也开发应用于血管与淋巴管生成研究的相关高品质试剂。目前ReliaTech提供近2800款产品，产品线主要包括重组蛋白(细胞因子、生长因子、可溶性受体)、抗体、ELISA试剂盒等。
- 注意
-
该页面的中文产品信息的翻译，仅供参考。准确的产品信息请以厂家的英文说明书为准。下单前，请浏览说明书确认。
-
